Business
Mesoblast shares savaged on poor COVID trial results – Sydney Morning Herald
The stem cell treatment hopeful plunged 41 per cent at the open after revealing its COVID research was unlikely to meet its goals.

The company, will complete the study, which had been aiming to recruit 300 patients, using the 223 patients already enrolled.
Its the second piece of tough news for Mesoblast, which is backed by high profile investors including billionaire Alex Waislitz, to be released this week, after phase 3 trial results of its heart failure drug caused the stock to plunge at the start of the week. The company released data on Tuesday showing its other product, Revascor, showed reduction in mortality of up to…
-
Noosa News20 hours ago
Katter and pregnant wife crash-land plane in outback Qld
-
Noosa News20 hours ago
Following Up Hottest 100 of Australian Songs Success with a Second Documentary About Your Life and Career: Jimmy Barnes Talks ‘Working Class Man’
-
Business21 hours ago
16 ASX 200 shares roar to multi-year highs amid new market milestone
-
Noosa News22 hours ago
Multibillion-dollar development delayed, date for Riverwalk reopening revealed